EUVIMEDEUVIMED entdecken
Crossref

Evaluation of the humoral response during ocrelizumab therapy in multiple sclerosis — an observational study

Joanna Rychter, Aleksandra Podlecka-Piętowska iD, Kinga Sujkowska, Janusz Sierdziński iD, Beata Zakrzewska-Pniewska iD, Monika Nojszewska iD

Neurologia i Neurochirurgia Polska · 21.07.2026

DOI: 10.5603/pjnns.108289 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neurologia i Neurochirurgia Polska, online erschienen am 21.07.2026. Verfasst von Joanna Rychter und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Medical University of Warsaw, Poland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Anti-CD20 monoclonal antibodies are widely used as high-efficacy treatment agents (HETAs) in multiple sclerosis (MS). In patients treated with ocrelizumab (OCR), reduced serum IgG levels are a common laboratory abnormality. Infections are among the most frequently observed adverse events during OCR therapy. Material and methods. We analyzed the humoral immune response during OCR therapy in 52 people with multiple sclerosis (PwMS) and assessed the safety of this treatment, including treatment-related adverse events and infection rates over a period of up to six years.

Results

After three years of treatment, immunoglobulin G (IgG) and IgG1 levels decreased, particularly in the relapsing-remitting MS (RMS) group. Higher body mass index (BMI) was associated with lower Ig levels and greater CD19+ cell depletion. Infections were more frequent in patients with relapses within 3 months prior to OCR initiation. Clinical implications/future directions. Ocrelizumab treatment for up to six years showed a manageable safety profile. Given the higher infection risk in patients with greater disease activity, earlier HETA initiation may be beneficial. The association between higher BMI and CD19+ cell depletion warrants further study to support personalized OCR dosing strategies.

Schlagwörter

Stichwörter der Autor:innen

anti-CD20 monoclonal antibodieshypogammaglobulinemiainfection riskmultiple sclerosisocrelizumabsecondary immunodeficiency

Autor:innen und Institutionen

  • Department of Neurology, Medical University of Warsaw, Poland.
  • Department of Neurology, Medical University of Warsaw, Poland. apodlecka@wum.edu.pl.
  • Department of Medical Informatics and Telemedicine, Medical University of Warsaw, Poland.

ORCID-Profile: Aleksandra Podlecka-Piętowska, Janusz Sierdziński, Beata Zakrzewska-Pniewska, Monika Nojszewska

Zitieren

APA

Rychter, J., Podlecka-Piętowska, A., Sujkowska, K., Sierdziński, J., Zakrzewska-Pniewska, B., & Nojszewska, M. (2026). Evaluation of the humoral response during ocrelizumab therapy in multiple sclerosis — an observational study. Neurologia i Neurochirurgia Polska. https://doi.org/10.5603/pjnns.108289

Vancouver

Rychter J, Podlecka-Piętowska A, Sujkowska K, Sierdziński J, Zakrzewska-Pniewska B, Nojszewska M. Evaluation of the humoral response during ocrelizumab therapy in multiple sclerosis — an observational study. Neurologia i Neurochirurgia Polska. 2026. doi:10.5603/pjnns.108289

BibTeX
@article{Rychter2026,
  author = {Rychter, Joanna and Podlecka-Piętowska, Aleksandra and Sujkowska, Kinga and Sierdziński, Janusz and Zakrzewska-Pniewska, Beata and Nojszewska, Monika},
  title = {Evaluation of the humoral response during ocrelizumab therapy in multiple sclerosis — an observational study},
  journal = {Neurologia i Neurochirurgia Polska},
  year = {2026},
  doi = {10.5603/pjnns.108289}
}
Kostenlos starten →